Genomic Health (GHDX) Tops Q2 EPS by 17c

Genomic Health (NASDAQ: GHDX) reported Q2 EPS of $0.23, $0.17 better than the analyst estimate of $0.06. Revenue for the quarter came in at $95.6 million versus the consensus estimate of $92.11 million.

GUIDANCE:

Genomic Health sees FY2018 EPS of $0.39-$0.56, versus the consensus of $0.45. Genomic Health sees FY2018 revenue of $366-382 million, versus the consensus of $377.07 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
• HCA Healthcare cuts 2026 profit outlook on insurance exchange losses
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance